Abstract
Imipramine is an antidepressant drug that is rarely associated with mild liver function abnormalities. These are usually minor and transient liver enzyme elevations which return to normal levels upon discontinuation of the drug. We describe a 48-year-old male who developed subfulminant hepatic failure after imipramine usage, with complete recovery within three months after discontinuation of the drug.
| Original language | English |
|---|---|
| Pages (from-to) | 79-80 |
| Number of pages | 2 |
| Journal | Pharmacopsychiatry |
| Volume | 29 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1996 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Hepatic failure associated with imipramine therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver